Ultragenyx Pharmaceutical Inc
(STU:UP0)
€
22.56
+0.77 (+3.53%)
Market Cap: 2.24 Bil
Enterprise Value: 1.68 Bil
PE Ratio: 0
PB Ratio: 0
GF Score: 71/100 Ultragenyx Pharmaceutical Inc at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (Virtual) Transcript
Apr 03, 2023 / 02:45PM GMT
Release Date Price:
€37
(+1.09%)
Debjit D. Chattopadhyay
Guggenheim Securities, LLC, Research Division - Senior Analyst of Biotechnology
Right. Good morning, and thank you for joining us -- I think Fifth Annual Guggenheim Genomic Medicines on Rare Disease Conference. I'm Debjit and my privilege to host Emil Kakkis, the CEO of Ultragenyx.
Emil D. Kakkis
Ultragenyx Pharmaceutical Inc. - Founder, President, CEO & Director
Thank you.
Debjit D. Chattopadhyay
Guggenheim Securities, LLC, Research Division - Senior Analyst of Biotechnology
Thank you, Emil, for being here. It's going to be a pretty interesting second half for you guys.
Questions & Answers
Debjit D. Chattopadhyay
Guggenheim Securities, LLC, Research Division - Senior Analyst of Biotechnology
So maybe we can start with the upcoming catalysts and where the pipeline currently stands?
Emil D. Kakkis
Ultragenyx Pharmaceutical Inc. - Founder, President, CEO & Director
Sure. We will
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot